Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study.

MLA

Yalan, Qin, et al. “Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): A Retrospective Cohort Study.” BMC Pharmacology & Toxicology, vol. 25, no. 1, Apr. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s40360-024-00753-7.

APA

Yalan, Q., Lingfang, H., Xisong, L., Run, L., Junjing, Z., & An, Z. (2024). Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study. BMC Pharmacology & Toxicology, 25(1), 1–8. https://doi.org/10.1186/s40360-024-00753-7

Chicago

Yalan, Qin, Hao Lingfang, Liu Xisong, Liang Run, Zhang Junjing, and Zhang’ An. 2024. “Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): A Retrospective Cohort Study.” BMC Pharmacology & Toxicology 25 (1): 1–8. doi:10.1186/s40360-024-00753-7.